Data to be presented at ACR meeting
Summary: Additional results from the ofatumumab Phase II study in RA will be
presented at the ACR/ARHP 2008 Annual Scientific Meeting on October 26, 2008.
Copenhagen, Denmark; October 8, 2008 - Genmab A/S (OMX: GEN) announced today
that data showing that rheumatoid arthritis patients who participated in the
ofatumumab (HuMax-CD20(R)) Phase II study achieved long lasting results at the
48 week follow up period. The data will be presented in a poster session at the
ACR/ARHP 2008 Annual Scientific Meeting in San Francisco, California on October
26, 2008. The full abstract can be found at
http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=2173&sKey=dce5e7b7-ccd
3-441c-97b8-23a76a10390d&cKey=16f927bb-6c7d-4766-b78d-ad9a4edcb3fc.
Ofatumumab is an investigational, new generation, human monoclonal antibody that
targets a distinct membrane proximal, small loop epitope (specific binding site)
of the CD20 molecule on the surface of B-cells. Ofatumumab is being developed to
treat chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, diffuse
large B-cell lymphoma, rheumatoid arthritis and relapsing remitting multiple
sclerosis under a co-development and commercialization agreement between Genmab
and GlaxoSmithKline. It is not yet approved for sale in any country.
About Genmab A/S
Genmab is a leading international biotechnology company focused on developing
fully human antibody therapeutics for unmet medical needs. Using cutting-edge
antibody technology, Genmab's world class discovery, development and
manufacturing teams have created and developed an extensive pipeline of products
for potential treatment of a variety of diseases including cancer and autoimmune
disorders. As Genmab advances towards a commercial future, we remain committed
to our primary goal of improving the lives of patients who are in urgent need of
new treatment options. For more information on Genmab's products and
technology, visit www.genmab.com.
This press release contains forward looking statements. The words “believe”,
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify
forward looking statements. Actual results or performance may differ materially
from any future results or performance expressed or implied by such statements.
The important factors that could cause our actual results or performance to
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical
trials including unforeseen safety issues, uncertainties related to product
manufacturing, the lack of market acceptance of our products, our inability to
manage growth, the competitive environment in relation to our business area and
markets, our inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary rights,
our relationships with affiliated entities, changes and developments in
technology which may render our products obsolete, and other factors. For a
further discussion of these risks, please refer to the section “Risk Management”
in Genmab's Annual Report, which is available on www.genmab.com. Genmab does
not undertake any obligation to update or revise forward looking statements in
this press release nor to confirm such statements in relation to actual results,
unless required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R);
HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM);
HuMax-CD32b(TM) and UniBody(R) are all trademarks of Genmab A/S.
Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M:
+45 25 27 47 13, E: hth@genmab.com
Investor News No. 10/2008
###
